Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Yucai Wang, MD MAYO CLINIC ROCHESTER Dr. Wang’s interest in cancer research began during his time in medical school at Nanjing University in China. He had lost two close family members to lymphoma and was drawn to pursue…
Researcher Spotlight: Christine Ryan, MD Dana-Farber Cancer Institute Upfront treatment of mantle cell lymphoma (MCL) typically involves an aggressive approach to treatment that offers the best chance of a durable and lasting response. Dr. Ryan is investigating a new first-line…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Preteesh Jain, MD, PhD UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER Chemotherapy-sparing treatment regimens are of great interest for many patients with lymphoma due to the variety of short- and long-term toxicities associated with These therapies. To this…
Researcher Spotlight: Ran Xu, PhD DANA FARBER CANCER INSTITUTE Many patients with mantle cell lymphoma (MCL) achieve complete remission with novel chimeric antigen receptor (CAR) T cell therapies, but some cancer cells remain that may eventually lead to relapse. Using…
Researcher Spotlight: Lydie Debaize, PhD Dana-Farber Cancer Institute Most patients treated for mantle cell lymphoma (MCL)achieve complete remission. Nevertheless, a significantnumber of patients will eventually relapse due to theregrowing of rare cancer cells remaining in the bodyafter treatment, which is known…
Researcher Spotlight: Allison Rosenthal, DO Mayo Clinic Arizona Mantle cell lymphoma (MCL) can present in a variety of ways, from slow-growing indolent to more aggressive forms with poorer outcomes. Currently a patient’s treatment plan is largely based on patient age…
Researcher Spotlight: Elise A. Chong, MD University of Pennsylvania Perelman School of Medicine Chimeric antigen receptor (CAR) T-cell therapy has been an effective treatment for any patients with B-cell lymphomas who don’t respond to other therapies, producing remissions in 30…
Researcher Spotlight: Jianguo Tao, MD, PhD H. Lee Moffitt Cancer Center With the success of ibrutinib in mantle cell lymphoma (MCL) and other B-cell lymphomas, researchers have become focused on the problem of treatment resistance – not only do a…